Granulators For Pharmaceutical Market Analysis & Forecast: 2026-2033

Granulators For Pharmaceutical Market Size and Share Analysis- 2026 to 2033

The granulators for pharmaceutical market are anticipated to grow at a CAGR of 8.43% with USD 1.41 Bn share in 2026 and is expected to reach USD 2.5 Bn in 2033. Increasing demand for oral dose medications (4 trillion defined daily doses) in the pharmaceutical industry drive growth.

Key Takeaways

• High sheer granulators is expected to account the largest share of 40% in 2026, With prescription medicines accounting for over 75% of pharmaceutical spending, mostly tablets and capsules, high shear granulators remain the dominant production equipment.
• Wet granulators will dominate with 60% in 2026, wet granulation remains the preferred method in various pharmaceutical formulations due to its ability to enhance powder flow, improve compressibility, as well as ensure uniformity in final dosage forms. Approximately 80% of the cases they end up with a wet granulation formulation due to processing issues.
• Pharmaceutical manufacturing companies hold the dominant share of 62% in 2026, pharmaceutical manufacturers produce a wide variemmty of dosage forms such as tablets, capsules, and powders. Tablets and capsules constitute over 70% of the total pharmaceutical dosage forms manufactured globally, requiring efficient granulation processes.
• North America is expected to acquire the dominant share of 40% in 2026, large pharmaceutical manufacturing base U.S. In May 2025, the Trump administration issued an executive order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines” directing the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) to ease permitting and inspection processes for domestic pharmaceutical facilities.

Rising Pharmaceutical Exports (2026) Will Propel Demand for Granulators for Pharmaceutical

To learn more about this report, Download Free Sample

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Growing pharmaceutical production is transforming the granulators for pharmaceutical industry in United States

The expanding pharmaceutical production landscape in the United States is significantly reshaping the demand and technological sophistication of granulators used in the industry. The surge in biopharmaceuticals, personalized medicine, as well as consistent manufacturing has supported companies to adopt advanced granulation technologies. Supporting this trend, the U.S. biopharmaceutical sector contributes an estimated USD 1.65 trillion to the economy, including USD 800 billion in direct output, showing the industry’s scale as well as its capacity to invest in conventional manufacturing equipment.

The influence of growing pharmaceutical production on granulator demand is further exemplified by the data from the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).

Current Events and Their Impact on the Granulators for Pharmaceutical Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Download Free Sample

Why is High Sheer Granulators Acquiring the Largest Market Share?

High sheer granulators are projected to account for the largest share in granulators for pharmaceutical in 2026, representing approximately 40% of the total volume. Due to their ability to process a broad variety of pharmaceutical materials, as well as enhanced control over granulation parameters, which contribute majorly to product consistency and quality. Granulation is particularly important for oral solids, as over 60% of pharmaceutical products are produced as tablets, capsules, coated tablets or similar, etc.

High Shear Granulators operate by vigorously mixing powders with granulating liquid, producing dense and uniform granules that are ideal for compression into tablets or encapsulation. Pharmaceutical manufacturers globally regard High Shear Granulators as indispensable when it comes to producing solid dosage forms with tight specifications related to particle size distribution, flowability, and compressibility.

In April 2025, Lancaster Products, an industry leader in specialized mixing and material processing equipment, announces the launch of the new K2 High Shear Mixer. This new mixer is designed to work accurately, quickly, and for different tasks, especially for small batches and testing.

Wet Granulators holds the Largest Market Share 

To learn more about this report, Download Free Sample

Based on granulation mechanism, wet granulators dominate the market, accounting for a significant 60% share in 2026, wet granulation remains the most established and widely used technique owing to its ability to enhance the physical and mechanical properties of the powdered drug, which is critical for ensuring uniform dosage and maintaining product efficacy. 46.7% of the tablets and 18.6% of the capsules employed at least one wet granulation step in the manufacturing process.

For instance, in February 2025, At INTERPHEX NYC, L.B. Bohle Showcased US Debut of Pharma Market’s First Wet Granulator with Integrated, Truly Continuous Dryer. The machine’s patented continuous drying process guarantees flow from raw material to dried granulation in a closed, truly continuous operation for improved product quality, increased flexibility and enhanced operator safety.

Which End User segment dominates the market?

Pharmaceutical manufacturing companies account for the largest share of 62% in 2026, these companies typically work at large scale with integrated production lines that require high-throughput granulation processes, driving demand for advanced as well as efficient granulators. The growth of the global pharmaceutical industry, with projected medicine spending set to rise at a 3%–6% CAGR to USD 1.6 trillion by 2025, showing increased production needs and investment in manufacturing capabilities.

Pharmaceutical manufacturing companies possess extensive in-house R&D and production capabilities, enabling them to execute cutting-edge granulation technologies suited for mass production.

Granulators For Pharmaceutical Market Trends

• Inclination towards continuous twin-screw granulation. This method contrasts with conventional batch granulation, offering key advantages, including continuous processing as well as good scalability.
• The revolution towards personalized medicine along with the growing emphasis on quality by design (QbD) frameworks are fueling the demand for precision granulation equipment. In 2025, personalized medicines topped one third of new drug approvals for fourth year in a row with 26 new personalized treatment approvals, 19 expanded indications for existing personalized medicines, and 17 significant new or expanded indications for 12 diagnostic testing products.
• Additionally, sustainability initiatives are supporting the development of energy-efficient as well as eco-friendly granulators. For instance, in November 2025, CMG Granulators is introducing a brand-new development: the new range of evacuation, dedusting and powder containment system solutions. The unit is the largest of the category and can evacuate, convey, dedust an amount of regrind of up to 7.000 kg/h. The entire new range of the so called Regrind Evac Systems, starts at a capacity of 200 kg/h and, through a selection of 10 different sizes, reaches the impressive capacity of 7.000 kg/h.

Regional Insights 

To learn more about this report, Download Free Sample

North America dominates owing to Growing prevalence of cataract surguries

North America account 40% market share in 2026, primarily due to its highly advanced pharmaceutical manufacturing infrastructure, stringent regulatory environment, along with substantial investments in pharmaceutical R&D. For instance, AstraZeneca announced a USD 50 billion investment in the United States by 2030 to expand medicines manufacturing and R&D capabilities, highlighting the region’s strong commitment to innovation as well as advanced production technologies.

The United States, which constitutes a major part of North America’s pharmaceutical landscape, has long been a global leader in pharmaceutical innovation and manufacturing efficiency. The USA is the world's largest pharmaceutical drug market. Nearly 70 % of Americans are on at least one prescription drug.

Asia Pacific Granulators for Pharmaceutical Market Trends

The Asia-Pacific region is poised to be as the fastest-growing region through 2026-2033, expanding at a CAGR of approximately 5.74%. The region hosts some of the world’s fastest-developing pharmaceutical industries, driven by an expanding base of generic drug manufacturers, increasing government health initiatives, and upgrades in manufacturing infrastructure. Generic drugs from the region account for 20% of global export volume, making countries like India the largest manufacturers of generics globally, which in turn creates the need for advanced granulation equipment.

Besides this, Countries like India, China, South Korea, and Japan are continuously expanding investment in pharmaceutical production as well as contract manufacturing to meet both internal population health needs and global export demand. China’s recent 14th Five-Year Plan identifies pharmaceutical manufacturing innovation as a major priority, with a focus on advancing production efficiency as well as drug quality through advanced equipment such as fluid bed granulators and high shear granulators.

Substantial Investments in Advanced Granulation Technologies is Accelerating the Granulators for Pharmaceutical Market Demand in United States

The United States Granulators for Pharmaceutical market is experiencing robust growth, fueled by high investment in advanced granulation technologies. For example, Merck Research Laboratories (MRL), the company’s human health R&D unit, invested USD 10.8 billion in 2025, a surge of USD 700 million from the previous year, showing the scale of funding directed toward innovative pharmaceutical manufacturing processes, such as high-throughput as well as precision granulation equipment.

The U.S. pharmaceutical industry is among the largest globally, supported by a dense network of contract manufacturing organizations (CMOs) and active pharmaceutical ingredient (API) producers. The Food and Drug Administration (FDA) has highly emphasized process optimization as well as quality control, encouraging manufacturers to adopt sophisticated granulation techniques such as high shear and fluid bed granulators to ensure uniform particle size and drug efficacy.

India Granulators for Pharmaceutical Market Trends

India contributes the highest share in the granulators for pharmaceutical market owing to its robust pharmaceutical manufacturing industry, supportive policies by government authorities, as well as growing domestic demand fueled by a large population and increasing healthcare awareness. India is recognized globally as the "pharmacy of the world," hosting a vast number of pharmaceutical companies ranging from multinational corporations to many small and medium enterprises. During April-March fiscal year 2025, pharmaceutical exports amounted to USD 30,466.85 million and from April-March FY24 to FY25, exports have grown by 9.40%.

Market Report Scope

Who are the Major Companies in Granulators for Pharmaceutical Industry

Some of the major key players in L.B. Bohle, Alexanderwerk, GEA Group Aktiengesellschaft, Frewitt S.A., LINXIS Group, Spraying Systems Co., Syntegon Technology GmbH, Romaco Group, Gebrüder Lödige Maschinenbau GmbH, and Glatt GmbH

Key News

• In March 2025, Aenova expanded its Bad Aibling site. With a total investment of around 20 million euros in new production as well as packaging lines, the site offers a modern, high-volume infrastructure for the production of effervescent products and blister packaging. Further investments will follow, including a new explosion-proof fluid bed granulator for organic granulation.
• In 2025, Canaan Technology released the FZM Series Fluid-bed Granulator, emphasizing miniaturization, modular design, and intelligent features, setting a new benchmark for laboratory-scale granulation.

Analyst Opinion

• Granulators are not just supporting equipment, they are mission-critical to pharmaceutical manufacturing. With over 60% of drugs formulated as tablets as well as capsules (IQVIA, 2024), the reliance on precise granulation is absolute. Any inefficiency in granulation directly risks dosage inconsistency, making advanced granulators indispensable rather than alternatives.
• The inclination toward advanced as well as intelligent granulation technologies is accelerating, and companies that fail to upgrade will fall behind. Innovations like Canaan Technology’s FZM Series Fluid-bed Granulator highlight the industry’s move toward modular, automated, as well as R&D-friendly systems, enabling faster formulation development and scale-up. At the same time, investments high investments by industries, such as Merck’s USD 10.8 billion R&D spend in 2025, underscore how seriously pharmaceutical leaders are investing in high-performance manufacturing infrastructure, including granulation.
• Sustainability is rapidly becoming a competitive differentiator, not just a compliance requirement. Equipment like CMG Granulators’ Regrind Evac System, with capacities up to 7,000 kg/h, demonstrates how manufacturers are prioritizing waste reduction, material recovery, and energy efficiency. In an environment of tightening environmental regulations, companies that adopt eco-efficient granulators early will gain cost advantages and regulatory ease, while laggards risk operational and compliance setbacks.

Market Segmentation

• By Product Type
  • Single Pot Granulators
  • High Sheer Granulators
  • Fluid Bed Granulators
  • Rapid Mixer Granulators
  • Oscillating Granulators
  • Others
• By Granulation Mechanism
  • Dry Granulators
  • Wet Granulators
  • Mixed Granulators
• By End User
  • Pharmaceutical Manufacturing Companies
  • Contract Manufacturing Organizations
  • Research Institutes
  • Others
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Pharmaceutical manufacturing equipment suppliers and OEMs
• Pharmaceutical production managers and process engineers
• Online granulation technology vendors and service providers
• Regulatory affairs specialists in pharmaceutical manufacturing
• Others

Databases

• FDA Drug Master Files Database
• PharmaCompass Industrial Database
• Global Trade Atlas (GTA)
• Pharmaceutical Manufacturing Database
• Others

Magazines

• Pharmaceutical Manufacturing Magazine
• Pharmaceutical Technology Magazine
• Contract Pharma Magazine
• Manufacturing Chemist Magazine
• Others

Journals

• International Journal of Pharmaceutics
• Pharmaceutical Development and Technology
• European Journal of Pharmaceutical Sciences
• Others

Newspapers

• Financial Times (Pharmaceuticals section)
• The Wall Street Journal (Healthcare & Pharmaceuticals)
• Reuters Health News
• Pharmaceutical Executive
• Others

Associations

• International Society for Pharmaceutical Engineering (ISPE)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• European Federation of Pharmaceutical Industries and Associations (EFPIA)
• American Association of Pharmaceutical Scientists (AAPS)
• Others

Public Domain Sources

• FDA.gov (U.S. Food and Drug Administration)
• europa.eu (European Medicines Agency)
• USPTO Patent Database
• WHO Technical Reports
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years